Medinet Medical Institute

MEDINET is a Japanese biotechnology company specializing in the field of regenerative medicine and cancer immunotherapy. Founded in 1995, the company provides comprehensive cell processing services and develops proprietary cell-based therapies, including dendritic cell vaccines and natural killer (NK) cell therapies. MEDINET operates advanced cell processing centers (CPCs) and collaborates with medical institutions to provide personalized cancer treatments. The company is publicly traded on the Tokyo Stock Exchange and is a pioneer in the commercialization of immuno-cell therapy in Japan. Their business model includes both the development of internal therapeutic pipelines and the provision of contract development and manufacturing organization (CDMO) services for other cell therapy developers.